MacroGenics Completes $122.5M Sale of Manufacturing Business to Bora Pharma
MGNX has more than doubled off its 52-week low of $1.29.
Summary
MacroGenics has finalized the sale of its manufacturing operations for $122.5 million, substantially increasing its cash position and enabling a sharper focus on its core drug development pipeline.
Key Events · M&A and Partnerships · MGNX
-
Completion of Asset Sale
MacroGenics completed the sale of its GMP manufacturing and CDMO business to Bora Pharmaceuticals for $122.5 million, effective June 30, 2026.
-
Significant Cash Infusion
The transaction adds $122.5 million in gross proceeds, substantially increasing the company's cash and cash equivalents by over $110 million on a pro forma basis.
-
Strategic Focus
The divestiture allows MacroGenics to streamline operations and concentrate resources on its core clinical-stage biopharmaceutical development.
-
Extended Cash Runway
This non-dilutive funding reinforces the company's previously announced extension of its cash runway through 2028.
Analysis · MGNX · Life Sciences
This 8-K announces the completion of the previously disclosed sale of MacroGenics' GMP manufacturing and CDMO business to Bora Pharmaceuticals for $122.5 million. This transaction significantly boosts the company's cash reserves, increasing cash and equivalents by over $110 million on a pro forma basis, and allows MacroGenics to focus entirely on its core biopharmaceutical development. The pro forma financials illustrate the substantial impact on the balance sheet and the shift in revenue streams, reinforcing the company's extended cash runway through 2028, as previously communicated.
At the time of this filing, MGNX was trading at $4.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $301.9M. The 52-week trading range was $1.29 to $5.08. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.